This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) 미래 성장

Future 기준 확인 3/6

SciClone Pharmaceuticals (Holdings) (는) 각각 연간 4.1% 및 12.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 24.1% 로 예상됩니다.

주요 정보

4.1%

수익 성장률

1.3%

EPS 성장률

Pharmaceuticals 수익 성장	10.9%
매출 성장률	12.7%
향후 자기자본 수익률	24.1%
애널리스트 커버리지	Low
마지막 업데이트	04 Jul 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02

수익 및 매출 성장 예측

SEHK:6600 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	4,086	1,233	N/A	N/A	1
12/31/2024	3,583	1,120	N/A	1,057	2
12/31/2023	3,156	1,122	1,327	1,404	N/A
9/30/2023	3,017	1,038	1,185	1,322	N/A
6/30/2023	2,878	953	1,043	1,239	N/A
3/31/2023	2,814	904	1,015	1,211	N/A
12/31/2022	2,750	855	987	1,184	N/A
9/30/2022	2,706	844	1,107	1,214	N/A
6/30/2022	2,662	833	1,226	1,245	N/A
3/31/2022	2,590	878	1,032	1,137	N/A
12/31/2021	2,518	923	839	1,029	N/A
9/30/2021	2,259	837	506	840	N/A
6/30/2021	2,089	779	358	724	N/A
3/31/2021	2,004	766	435	853	N/A
12/31/2020	1,919	754	512	981	N/A
9/30/2020	2,001	817	657	974	N/A
12/31/2019	1,708	615	999	1,032	N/A
12/31/2018	1,409	535	143	167	N/A
12/31/2017	1,213	20	143	154	N/A
6/30/2017	1,166	294	N/A	242	N/A
3/31/2017	1,146	258	N/A	187	N/A
12/31/2016	1,112	213	N/A	240	N/A
9/30/2016	1,060	246	N/A	221	N/A
6/30/2016	1,072	257	N/A	231	N/A
3/31/2016	1,034	183	N/A	214	N/A
12/31/2015	1,021	191	N/A	211	N/A
9/30/2015	991	130	N/A	200	N/A
6/30/2015	913	102	N/A	210	N/A
3/31/2015	879	186	N/A	222	N/A
12/31/2014	836	156	N/A	171	N/A
9/30/2014	774	133	N/A	148	N/A
6/30/2014	790	140	N/A	173	N/A
3/31/2014	770	68	N/A	17	N/A
12/31/2013	769	66	N/A	58	N/A
9/30/2013	780	78	N/A	88	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 6600 의 연간 예상 수익 증가율( 4.1% )이 saving rate( 2.2% 보다 높습니다. ).

수익 vs 시장: 6600 의 연간 수익( 4.1% ) Hong Kong 시장( 11.6% 보다 느리게 성장할 것으로 예상됩니다. 11.6% 연간).

고성장 수익: 6600 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 6600 의 수익(연간 12.7% ) Hong Kong 시장( 7.8% 보다 빠르게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 6600 의 수익(연간 12.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 6600 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 24.1 %)

This company listing is no longer active

SciClone Pharmaceuticals (Holdings) 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Recent updates

SciClone Pharmaceuticals (Holdings) Limited Announces Retirement of Wang Haixia as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 20%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings: EPS and revenues miss analyst expectations

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Investor sentiment deteriorated over the past week

Non-Executive Director Xiaozhuo Wang has left the company

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.13 in FY 2019)

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

SciClone Pharmaceuticals (Holdings) Limited has completed an IPO in the amount of HKD 2.180509 billion.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견